“…The prevalence of HAD on the severe end of the spectrum has declined with antiretroviral therapy (ART) (Baker et al, 2015;Gates & Cysique, 2016), but mild to moderate cognitive deficits in HIV remain an issue (Manji, Jager, & Winston, 2013;Underwood et al, 2017;Vivithanaporn et al, 2010). Accelerated loss of brain tissue, specifically, in frontal and sensorimotor neocortices, thalamus, and hippocampus-related to disease duration and CD4 nadir (Cohen et al, 2010;Pfefferbaum et al, 2014)-may represent a risk factor for premature cognitive compromise if not dementia (Ances, Ortega, Vaida, Heaps, & Paul, 2012;Pfefferbaum et al, 2014;Pfefferbaum et al, 2018;Sanford et al, 2018). In seeking a neural substrate for HAD, an early imaging study in HIV-infected individuals found no relation between neuropsychological test performance and hippocampal volume (Kieburtz et al, 1996); a later stereological study found no statistically significant differences in hippocampal neuronal number between nine HIV/AIDS patients and 10 controls (Korbo & West, 2000).…”